Zimmer Biomet (ZBH) Stock Forecast & Price Target

$101.77

-0.51 (-0.50%)

(As of 10/8/2024 ET)

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
12

Buy
7

Based on 21 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 12 have given a hold rating, and 7 have given a buy rating for ZBH.

Consensus Price Target

$124.53
22.36% Upside

According to the 21 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $124.53. The highest price target for ZBH is $150.00, while the lowest price target for ZBH is $107.00. The average price target represents a forecasted upside of 22.36% from the current price of $101.77.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

ZBH Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	12 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$124.53	$126.00	$130.59	$144.89
Forecasted Upside	22.36% Upside	20.22% Upside	22.16% Upside	30.91% Upside
Consensus Rating	Hold	Hold	Hold	Hold

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	S&P 500
Consensus Rating Score	2.24	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	22.54% Upside	10,819.51% Upside	7.88% Upside
News Sentiment Rating	Neutral News See Recent ZBH News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$130.00 ➝ $120.00	+17.86%
10/3/2024	BTIG Research 2 of 5 stars		Lower Target	Buy ➝ Buy	$134.00 ➝ $126.00	+20.56%
10/1/2024	Evercore ISI 2 of 5 stars		Lower Target	In-Line ➝ In-Line	$113.00 ➝ $110.00	+2.31%
9/17/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
9/16/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$125.00 ➝ $120.00	+12.46%
9/13/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$117.00 ➝ $112.00	+4.52%
Get the Latest News and Ratings for ZBH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.
9/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$120.00 ➝ $115.00	+10.09%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
9/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$143.00 ➝ $119.00	+13.61%
8/8/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$138.00 ➝ $128.00	+19.15%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$112.00 ➝ $107.00	-0.07%
8/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$155.00 ➝ $145.00	+37.01%
8/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$155.00 ➝ $145.00	+37.01%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$130.00 ➝ $120.00	+12.21%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$134.00 ➝ $120.00	+12.25%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $115.00	+5.96%
5/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$130.00 ➝ $125.00	+9.39%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$129.00	+12.04%
5/21/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.89%
11/13/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$160.00 ➝ $140.00	+31.14%
10/20/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$120.00	+14.56%
5/18/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/18/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$160.00 ➝ $165.00	+22.19%
5/3/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$121.00 ➝ $147.00	+4.13%
5/3/2023	FIG Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral
5/3/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
5/3/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$136.00 ➝ $152.00	+6.29%
3/31/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Hold	$115.00 ➝ $130.00	+2.56%
2/6/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$125.00 ➝ $140.00	+8.15%
11/23/2022	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$116.00 ➝ $124.00	+7.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:19 PM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 7, 2024. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

Zimmer Biomet has a market capitalization of $21.69 billion, indicating a strong position in the market.
The company's P/E ratio of 23.06 suggests potential undervaluation compared to industry peers.
Recent quarterly earnings report showed a positive surprise with earnings per share beating estimates by $0.02, indicating strong financial performance.
With a dividend yield of 0.90%, Zimmer Biomet offers investors a steady income stream.
The company's 200-day simple moving average of $115.11 indicates a stable long-term price trend.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

Analyst ratings have been mixed, with some lowering price targets, suggesting uncertainty in the stock's future performance.
The company's stock has a 12-month high of $133.90, potentially limiting short-term growth opportunities.
Debt-to-equity ratio of 0.31 may indicate higher financial leverage, increasing risk for investors.
Recent price target reductions by analysts could signal concerns about future growth prospects.
Current stock price may not fully reflect potential risks and uncertainties in the market.

ZBH Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $124.53, with a high forecast of $150.00 and a low forecast of $107.00.
: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 12 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
: According to analysts, Zimmer Biomet's stock has a predicted upside of 22.36% based on their 12-month stock forecasts.
: Zimmer Biomet has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Citigroup, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James, Robert W. Baird, Royal Bank of Canada, TD Cowen, Truist Financial, UBS Group, and Wolfe Research in the past 90 days.
: Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.